Shares of Pro Medicus Ltd (PME.AU), an Australian health imaging firm, plummeted 5.02% in Thursday's trading session following a report from Jefferies that revised down the company's near-term growth forecasts.
The brokerage firm cited the stepped minimum nature of the Trinity contract as a key factor in their decision to adjust Pro Medicus' growth projections. Jefferies also trimmed its estimates for the company's cardiology contribution, resulting in a reduction of the implied market share increase to 14% in FY26, down from the previous estimate of 15%.
Despite these downward revisions, Jefferies maintained its A$250 price target on Pro Medicus and kept its 'Hold' rating unchanged. This suggests that while near-term expectations have been tempered, the long-term outlook for the company remains relatively stable in the brokerage's view. It's worth noting that Pro Medicus' stock has already been under pressure this year, with shares down 9% year-to-date prior to today's decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.